JPH07215833A - Skin external preparation - Google Patents

Skin external preparation

Info

Publication number
JPH07215833A
JPH07215833A JP2627494A JP2627494A JPH07215833A JP H07215833 A JPH07215833 A JP H07215833A JP 2627494 A JP2627494 A JP 2627494A JP 2627494 A JP2627494 A JP 2627494A JP H07215833 A JPH07215833 A JP H07215833A
Authority
JP
Japan
Prior art keywords
skin
external preparation
skin external
xanthene
oxidation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2627494A
Other languages
Japanese (ja)
Other versions
JP3498857B2 (en
Inventor
Tatsuro Yamamura
達郎 山村
Fukiko Yamada
冨貴子 山田
Tomihiro Nishiyama
富博 西山
Takashi Ishida
貴史 石田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noevir Co Ltd
Original Assignee
Noevir Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noevir Co Ltd filed Critical Noevir Co Ltd
Priority to JP02627494A priority Critical patent/JP3498857B2/en
Publication of JPH07215833A publication Critical patent/JPH07215833A/en
Application granted granted Critical
Publication of JP3498857B2 publication Critical patent/JP3498857B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

PURPOSE:To obtain a safe skin external preparation excellent in stability to oxidation, mitigating skin aging symptoms due to peroxidation of dermal lipids, and causing no skin irritation or skin sensitization. CONSTITUTION:The characteristic of this skin external preparation comprises being formulated with a xanthene-2,7-diol compound of the formula (R is H, an alkyl, an alkenyl or an aryl). It is sufficient that as low as 1-50mug of this compound be formulated in 100g of the skin external preparation. This skin external preparation has the following advantages: increase in its peroxide value does not occur even after stored for a long period (namely, stable to oxidation) and aging symptoms due to dermal lipoperoxide formation caused by ultraviolet radiation or metabolism can be effectively lowered or prevented.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、優れた抗酸化性を有す
るキサンテン-2,7-ジオール類を配合して成る、保存安
定性に優れ、且つ皮膚の老化を防止又は予防し得る皮膚
外用剤に関する。
FIELD OF THE INVENTION The present invention relates to xanthene-2,7-diols having excellent antioxidative properties, and is excellent in storage stability and capable of preventing or preventing skin aging. Regarding agents.

【0002】[0002]

【従来の技術】多くの場合、化粧料や皮膚外用剤は種々
の油脂と水溶性原料とを組み合わせて調製され、通常油
脂の酸化を防ぐため抗酸化剤が配合される。これら抗酸
化剤としては、ブチルヒドロキシアニソール(BH
A),ジブチルヒドロキシトルエン(BHT),没食子
酸プロピル等の没食子酸誘導体,ビタミンE及びそのエ
ステル等が用いられる。
2. Description of the Related Art In many cases, cosmetics and external preparations for skin are prepared by combining various fats and oils and water-soluble raw materials, and usually antioxidants are added to prevent the fats and oils from being oxidized. Butyl hydroxyanisole (BH
A), dibutylhydroxytoluene (BHT), gallic acid derivatives such as propyl gallate, vitamin E and its ester, etc. are used.

【0003】また、紫外線や代謝により生じた活性酸素
種により皮膚の脂質が過酸化され、かかる過酸化脂質が
皮膚の老化を引き起こす一因となっていることが明らか
になるにつれ、かかる活性酸素種を捕捉する抗酸化剤を
化粧料や皮膚外用剤に配合して、過酸化脂質の生成を防
止し、皮膚の老化防止を図る試みがなされている。
Further, as it has become clear that lipids in the skin are peroxidized by active oxygen species generated by ultraviolet rays and metabolism, and that such lipid peroxides are one of the causes of aging of the skin, the active oxygen species are Attempts have been made to prevent the generation of lipid peroxides and prevent skin aging by blending an antioxidative agent that captures the above with cosmetics and skin external preparations.

【0004】しかし、従来用いられていた抗酸化剤のう
ち、BHA,BHT等を配合した化粧料や皮膚外用剤は
接触皮膚炎を起こしやすく、皮膚感作性も懸念される。
一方、没食子酸誘導体やビタミンE類は抗酸化活性が十
分でなく、これらを配合した皮膚外用剤において、特に
皮膚脂質の過酸化に起因する皮膚の老化防止を期待する
場合、十分な効果が得られなかった。
However, among the conventionally used antioxidants, cosmetics and external preparations for the skin containing BHA, BHT and the like are liable to cause contact dermatitis and skin sensitization is concerned.
On the other hand, gallic acid derivatives and vitamin Es do not have sufficient antioxidative activity, and a skin external preparation containing them has a sufficient effect, especially when it is expected to prevent skin aging due to peroxidation of skin lipids. I couldn't do it.

【0005】[0005]

【発明が解決しようとする課題】本発明は上記の課題を
解決し、外用剤中に配合された油脂の酸敗を防止して優
れた製品安定性を有する皮膚外用剤を提供するのみでな
く、皮膚の過酸化に起因する老化現象を有効に防止する
ことができ、且つ皮膚刺激性や皮膚感作性等のない安全
な皮膚外用剤を提供することを目的とする。
The present invention solves the above-mentioned problems and not only provides a skin external preparation having excellent product stability by preventing rancidity of oils and fats mixed in the external preparation, An object of the present invention is to provide a safe external preparation for skin, which can effectively prevent the aging phenomenon caused by skin peroxidation and has no skin irritation or skin sensitization.

【0006】[0006]

【課題を解決するための手段】本発明者らは上記の課題
を解決するべく、皮膚外用剤に配合したとき少量で有効
な抗酸化活性を示し、且つ皮膚等への好ましくない影響
がなく、さらに外用剤製剤の安定性にも悪影響を与えな
い抗酸化剤の検討を行った。その結果、一般式1で示さ
れるキサンテン-2,7-ジオール類に高い抗酸化活性を見
い出し、本発明を完成するに至った。
Means for Solving the Problems In order to solve the above-mentioned problems, the present inventors show effective antioxidant activity in a small amount when compounded in a skin external preparation, and have no unfavorable effects on the skin, Furthermore, an antioxidant that does not adversely affect the stability of the preparation for external use was examined. As a result, a high antioxidant activity was found in the xanthene-2,7-diols represented by the general formula 1, and the present invention was completed.

【0007】一般式1において、R基は水素,アルキ
ル,アルケニル又はアリール基であり、特に水素、メチ
ル,エチル,イソプロピル等の低級アルキル基、フェニ
ル基等が好ましい。
In the general formula 1, R group is hydrogen, alkyl, alkenyl or aryl group, and hydrogen, lower alkyl group such as methyl, ethyl and isopropyl, phenyl group and the like are preferable.

【0008】本発明において使用するキサンタン-2,7-
ジオール類の抗酸化活性について以下に示す。油脂に対
する抗酸化性の指標としてリノール酸ミセル系、生体膜
内における抗酸化性の指標としてリポソーム系を用いて
検討を行った。まず、リノール酸ミセル系における抗酸
化性は、リノール酸1.68mg(60mM),ポリオ
キシエチレン(20)ソルビタンモノラウレート(ツイーン
20)3.6g,0.5M2,2'-Azobis-(2-amidinoprop
ane)hydrochloride(AAPH)1ml,水120ml
より成るミセル水溶液にキサンテン-2,7-ジオール類
2.0μmolを加え、酸素電極を用いて溶存酸素量を
測定し、これより酸化誘導時間(I.P.)を算出して抗酸
化活性を評価した。また、リポソーム系における抗酸化
性は、大豆レシチン150mg,AAPH0.8mmo
l,0.1M塩化ナトリウム水溶液120mlに、キサ
ンテン-2,7-ジオール類1.50μmolを加えて大豆
レシチンリポソームを調製し、同様に酸素電極による溶
存酸素量の測定からI.P.を求めて評価した。結果を表1
に示す。
Xanthan-2,7- used in the present invention
The antioxidant activity of diols is shown below. A linoleic acid micelle system was used as an index of antioxidant properties against oils and fats, and a liposome system was used as an index of antioxidant properties in biological membranes. First, the antioxidant properties in the linoleic acid micelle system were as follows: linoleic acid 1.68 mg (60 mM), polyoxyethylene (20) sorbitan monolaurate (Tween 20) 3.6 g, 0.5M2,2'-Azobis- (2 -amidinoprop
ane) hydrochloride (AAPH) 1ml, water 120ml
Xanthene-2,7-diols (2.0 μmol) were added to the micelle aqueous solution, and the amount of dissolved oxygen was measured using an oxygen electrode, and the oxidation induction time (IP) was calculated from this to evaluate the antioxidant activity. In addition, the antioxidant property in the liposome system is that soybean lecithin 150 mg, AAPH 0.8 mmo
Soybean lecithin liposomes were prepared by adding 1.50 μmol of xanthene-2,7-diols to 120 ml of a 0.1 M aqueous sodium chloride solution, and IP was determined by measuring the dissolved oxygen content by an oxygen electrode in the same manner. The results are shown in Table 1.
Shown in.

【表1】 [Table 1]

【0009】表1において、試験に供したキサンテン-
2,7-ジオール(R=水素,メチル,エチル,イソプロピ
ル,フェニル)は、いずれも抗酸化剤無添加の対照に比
べて大幅にI.P.を延長し、抗酸化剤として汎用されるα
-トコフェロールや、式2で示されるクロマノールを添
加した場合と比較しても、I.P.延長効果は大きい。
In Table 1, xanthene used in the test
All 2,7-diols (R = hydrogen, methyl, ethyl, isopropyl, phenyl) prolong IP significantly compared to the control without antioxidant and are widely used as antioxidants α
-Compared with the addition of tocopherol or chromanol of formula 2, the effect of IP extension is large.

【化2】 [Chemical 2]

【0010】続いて、キサンテン-2,7-ジオール類の細
胞毒性について以下に示す。細胞毒性は、正常ヒト由来
の線維芽細胞を96穴プレートに播種し37℃で24時
間培養後、培養液を牛胎仔血清添加DMEM培地から高
カルシウム,高マグネシウムMCDB153培地に交換
し、さらに37℃で24時間培養した後、各試料溶液1
00μlを添加し、37℃にて1時間或いは6時間接触
させて行った。試料溶液は、各キサンテン-2,7-ジオー
ルをジメチルスルホキシド(DMSO)に溶解し、これ
を高カルシウム,高マグネシウムMCDB153培地に
分散させて調製した。細胞の生存率をMTT(2-(4,5-d
imethyl-2-thiazolyl)-3,5-diphenyltetrazolium bromi
de)還元法により求め、半数致死量(LD50)を算出し
たところ、1時間接触ではLD50値は50μg或いは1
00μg以上と高く、6時間接触の場合でもBHTに比
べて高いLD50値を示し、特にR=水素のキサンテン-
2,7-ジオールにおいては、LD50値が420μgと安全
性が高かった。
Next, the cytotoxicity of xanthene-2,7-diols will be shown below. For cytotoxicity, normal human-derived fibroblasts were seeded on a 96-well plate and cultured at 37 ° C for 24 hours, and then the culture medium was changed from fetal bovine serum-containing DMEM medium to high-calcium and high-magnesium MCDB153 medium, and further 37 ° C. After culturing for 24 hours in each sample solution 1
00 μl was added, and contact was performed at 37 ° C. for 1 hour or 6 hours. The sample solution was prepared by dissolving each xanthene-2,7-diol in dimethyl sulfoxide (DMSO) and dispersing this in a high calcium and high magnesium MCDB153 medium. The viability of the cells is measured by MTT (2- (4,5-d
imethyl-2-thiazolyl) -3,5-diphenyltetrazolium bromi
de) Obtained by the reduction method and the half-lethal dose (LD50) was calculated. The LD50 value was 50 μg or 1 at 1 hour contact.
It is as high as 00 μg or more, and shows a higher LD50 value than that of BHT even when contacted for 6 hours. Especially, R = hydrogen xanthene-
With 2,7-diol, the LD50 value was 420 μg, which was high in safety.

【0011】[0011]

【作用】本発明においては、キサンテン-2,7-ジオール
類は皮膚外用剤100g中に1μg〜50μg程度の極
微量を配合する。本発明に係る皮膚外用剤は、長期間保
存したときも過酸化物価の上昇が見られず、酸化に対し
て安定であり、さらに、紫外線や代謝により生じる皮膚
の過酸化脂質生成に起因する老化症状を有効に改善し且
つ防止することができる。また、本発明に係る皮膚外用
剤は、皮膚の状態を美化する種々の形態の化粧料として
も提供することができる。
In the present invention, the xanthene-2,7-diols are added in an extremely small amount of about 1 μg to 50 μg in 100 g of the skin external preparation. The external preparation for skin according to the present invention does not show an increase in peroxide value even when stored for a long period of time, is stable against oxidation, and further, is aged due to lipid peroxidation of skin caused by ultraviolet rays or metabolism. Symptoms can be effectively improved and prevented. The external preparation for skin according to the present invention can also be provided as a cosmetic in various forms for beautifying the skin condition.

【0012】[0012]

【実施例】さらに本発明について、実施例により詳細に
説明する。表2に本発明の実施例に係る皮膚用クリーム
の処方を比較例とともに示す。実施例1,2,3はそれ
ぞれキサンテン-2,7-ジオールのR=水素,メチル,フ
ェニルの化合物を抗酸化剤として配合し、比較例1,2
は抗酸化剤としてそれぞれ酢酸トコフェロール,BHT
を配合したものである。これらは次のようにして製造す
る。表2中、(1)〜(7)の油相成分を混合,溶解して均一
とし、75℃に加熱する。一方、(8),(10),(12)を混
合,溶解して75℃に加熱し、これに上記油相成分を添
加して予備乳化した後、ホモミキサーにて均一に乳化す
る。その後冷却し、50℃にて(9),(11)を添加する。
EXAMPLES The present invention will be described in more detail with reference to Examples. Table 2 shows the formulations of the skin cream according to the examples of the present invention together with comparative examples. In Examples 1, 2, and 3, compounds of R = hydrogen, methyl, and phenyl of xanthene-2,7-diol were compounded as antioxidants, and Comparative Examples 1, 2 and 3 were used.
Are tocopherol acetate and BHT, respectively, as antioxidants
It is a mixture of. These are manufactured as follows. In Table 2, the oil phase components (1) to (7) are mixed, dissolved and homogenized, and heated to 75 ° C. On the other hand, (8), (10) and (12) are mixed, dissolved and heated to 75 ° C., and the above oil phase component is added thereto for preliminary emulsification and then homogenized with a homomixer. After cooling, (9) and (11) are added at 50 ° C.

【表2】 [Table 2]

【0013】本発明の実施例について、皮膚の老化症状
の防止効果,酸化安定性及び皮膚刺激性を検討した。皮
膚の老化症状の防止効果は実際に使用試験を行って評価
した。使用試験は、日常戸外で作業する40〜60才代
のパネラー20名を1群とし、実施例及び比較例をブラ
インドにて各群に5月〜7月の3ヶ月間使用させ、使用
後の皮膚のしわ,きめ,はり及び肌荒れの改善状況を観
察し、評価した。皮膚のしわ,きめ及び肌荒れの改善状
況については写真撮影による外観観察により、皮膚のは
りについては皮膚弾性の測定により評価し、しわについ
ては「軽減」,「やや軽減」,「変化なし」,「増
加」、きめ及びはりについては「良好」,「やや良
好」,「変化なし」,「悪化」又は「低下」、肌荒れに
ついては「改善」,「やや改善」,「変化なし」,「悪
化」の各4段階で評価した。結果は、各評価を得たパネ
ラー数にて表3に示した。
In the examples of the present invention, the effect of preventing skin aging symptoms, oxidative stability and skin irritation were examined. The effect of preventing skin aging symptoms was evaluated by actually conducting a use test. In the use test, 20 panelists in their 40s to 60s working daily outdoors were set as one group, and the examples and comparative examples were blindly used in each group for 3 months from May to July. The state of improvement of skin wrinkles, texture, acupuncture and rough skin was observed and evaluated. The improvement of skin wrinkles, texture and rough skin is evaluated by observing the appearance by photographing, and the skin elasticity is evaluated by measuring skin elasticity, and wrinkles are “reduced”, “slightly reduced”, “no change”, “ "Increase", "Good", "Slightly good", "No change", "Aggravated" or "Degraded" for texture and acupuncture, "Improved", "Slightly improved", "No change", "Aggravated" for rough skin It was evaluated in each of 4 stages. The results are shown in Table 3 by the number of panelists who obtained each evaluation.

【表3】 [Table 3]

【0014】また、酸化安定性はAOM法(Active oxy
gen method)により評価し、「◎;非常に安定」、
「○;ほぼ安定」、「△;やや不安定」、「×;不安
定」の4段階で表した。皮膚刺激性は各試料につき30
名のパネラーを用いて48時間のクローズドパッチテス
トを行い、結果を表4に示す判定基準により評価し、3
0名の皮膚刺激指数の平均値にて表した。これら試験の
結果は表3にまとめて示した。
The oxidative stability is determined by the AOM method (Active oxy
gen method) and evaluated as “◎; very stable”,
It was expressed in four stages: "○; almost stable", "△; somewhat unstable", and "x;unstable". Skin irritation is 30 for each sample
A closed patch test was conducted for 48 hours using a well-known panel, and the results were evaluated according to the criteria shown in Table 4 and 3
It was represented by the average value of the skin irritation index of 0 persons. The results of these tests are summarized in Table 3.

【表4】 [Table 4]

【0015】表3より明らかなように、本発明の実施例
においては、いずれもごく少量のキサンテン-2,7-ジオ
ール類の配合により良好な酸化安定性を示し、皮膚に対
しても優れたしわの軽減、きめ,はりの向上、肌荒れの
改善といった老化症状の緩和作用が認められる。また、
皮膚刺激指数はいずれも低く、抗酸化剤として酢酸トコ
フェロールを用いた比較例1と同様、良好な安全性を示
した。これに対し、比較例1では酸化安定性が十分では
なく、皮膚の老化症状の緩和作用も不十分である。一
方、抗酸化剤としてBHTを配合した比較例2では、酸
化安定性は良好であるが皮膚刺激性が認められ、パネラ
ーによっては皮膚症状が悪化した例も認められた。
As is clear from Table 3, in each of the examples of the present invention, the addition of a very small amount of xanthene-2,7-diol showed good oxidative stability and was excellent for the skin. There is a palliative effect of aging symptoms such as wrinkle reduction, texture and astringency improvement, and rough skin improvement. Also,
The skin irritation index was low, showing good safety as in Comparative Example 1 using tocopherol acetate as an antioxidant. On the other hand, in Comparative Example 1, the oxidative stability is not sufficient and the action of alleviating the aging symptoms of skin is also insufficient. On the other hand, in Comparative Example 2 in which BHT was blended as an antioxidant, oxidative stability was good, but skin irritation was observed, and there were cases in which skin symptoms worsened depending on the panelists.

【0016】[0016]

【本発明の効果】以上詳述したように、本発明により、
非常に酸化安定性に優れ、且つ皮膚刺激性や感作性がな
く安全で、さらに皮膚脂質の過酸化に起因する皮膚の老
化を有効に防止,改善し得る皮膚外用剤を提供すること
ができた。
As described in detail above, according to the present invention,
It is possible to provide a skin external preparation that has excellent oxidative stability, is safe without skin irritation and sensitization, and can effectively prevent and improve skin aging caused by peroxidation of skin lipids. It was

Claims (2)

【特許請求の範囲】[Claims] 【請求項1】 一般式1で示されるキサンテン-2,7-ジ
オール類を配合することを特徴とする皮膚外用剤。 【化1】
1. An external preparation for skin, which comprises xanthene-2,7-diols represented by the general formula 1. [Chemical 1]
【請求項2】 皮膚外用剤が化粧料であることを特徴と
する、請求項1に記載の皮膚外用剤。
2. The external preparation for skin according to claim 1, wherein the external preparation for skin is a cosmetic.
JP02627494A 1994-01-28 1994-01-28 External preparation for skin Expired - Fee Related JP3498857B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP02627494A JP3498857B2 (en) 1994-01-28 1994-01-28 External preparation for skin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP02627494A JP3498857B2 (en) 1994-01-28 1994-01-28 External preparation for skin

Publications (2)

Publication Number Publication Date
JPH07215833A true JPH07215833A (en) 1995-08-15
JP3498857B2 JP3498857B2 (en) 2004-02-23

Family

ID=12188714

Family Applications (1)

Application Number Title Priority Date Filing Date
JP02627494A Expired - Fee Related JP3498857B2 (en) 1994-01-28 1994-01-28 External preparation for skin

Country Status (1)

Country Link
JP (1) JP3498857B2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102985415A (en) * 2010-07-09 2013-03-20 皮埃尔·法布尔皮肤化妆品公司 Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders
WO2014123102A1 (en) * 2013-02-08 2014-08-14 三菱瓦斯化学株式会社 Compound, material for forming underlayer film for lithography, underlayer film for lithography, and pattern formation method
US9809601B2 (en) 2013-02-08 2017-11-07 Mitsubishi Gas Chemical Company, Inc. Compound, material for forming underlayer film for lithography, underlayer film for lithography and pattern forming method
US20170349564A1 (en) 2014-12-25 2017-12-07 Mitsubishi Gas Chemical Company, Inc. Compound, resin, material for forming underlayer film for lithography, underlayer film for lithography, pattern forming method, and purification method
JP2018154600A (en) * 2017-03-21 2018-10-04 三菱瓦斯化学株式会社 Compound, resin, composition, patterning method, and purifying method
US10377734B2 (en) 2013-02-08 2019-08-13 Mitsubishi Gas Chemical Company, Inc. Resist composition, method for forming resist pattern, polyphenol derivative for use in the composition
US11137686B2 (en) 2015-08-31 2021-10-05 Mitsubishi Gas Chemical Company, Inc. Material for forming underlayer film for lithography, composition for forming underlayer film for lithography, underlayer film for lithography and production method thereof, and resist pattern forming method
US11143962B2 (en) 2015-08-31 2021-10-12 Mitsubishi Gas Chemical Company, Inc. Material for forming underlayer film for lithography, composition for forming underlayer film for lithography, underlayer film for lithography and production method thereof, pattern forming method, resin, and purification method
US11243467B2 (en) 2015-09-10 2022-02-08 Mitsubishi Gas Chemical Company, Inc. Compound, resin, resist composition or radiation-sensitive composition, resist pattern formation method, method for producing amorphous film, underlayer film forming material for lithography, composition for underlayer film formation for lithography, method for forming circuit pattern, and purification method
US11256170B2 (en) 2015-03-31 2022-02-22 Mitsubishi Gas Chemical Company, Inc. Compound, resist composition, and method for forming resist pattern using it
US11480877B2 (en) 2015-03-31 2022-10-25 Mitsubishi Gas Chemical Company, Inc. Resist composition, method for forming resist pattern, and polyphenol compound used therein

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102985415A (en) * 2010-07-09 2013-03-20 皮埃尔·法布尔皮肤化妆品公司 Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders
US10377734B2 (en) 2013-02-08 2019-08-13 Mitsubishi Gas Chemical Company, Inc. Resist composition, method for forming resist pattern, polyphenol derivative for use in the composition
CN104981463A (en) * 2013-02-08 2015-10-14 三菱瓦斯化学株式会社 Compound, material for forming underlayer film for lithography, underlayer film for lithography, and pattern formation method
JPWO2014123102A1 (en) * 2013-02-08 2017-02-02 三菱瓦斯化学株式会社 COMPOUND, LITHOGRAPHIC LOWER FILM FORMING MATERIAL, LITHOGRAPHY LOWER FILM AND PATTERN FORMING METHOD
US9809601B2 (en) 2013-02-08 2017-11-07 Mitsubishi Gas Chemical Company, Inc. Compound, material for forming underlayer film for lithography, underlayer film for lithography and pattern forming method
US9828355B2 (en) 2013-02-08 2017-11-28 Mitsubishi Gas Chemical Company, Inc. Compound, material for forming underlayer film for lithography, underlayer film for lithography and pattern forming method
WO2014123102A1 (en) * 2013-02-08 2014-08-14 三菱瓦斯化学株式会社 Compound, material for forming underlayer film for lithography, underlayer film for lithography, and pattern formation method
US10745372B2 (en) 2014-12-25 2020-08-18 Mitsubishi Gas Chemical Company, Inc. Compound, resin, material for forming underlayer film for lithography, underlayer film for lithography, pattern forming method, and purification method
US20170349564A1 (en) 2014-12-25 2017-12-07 Mitsubishi Gas Chemical Company, Inc. Compound, resin, material for forming underlayer film for lithography, underlayer film for lithography, pattern forming method, and purification method
US11256170B2 (en) 2015-03-31 2022-02-22 Mitsubishi Gas Chemical Company, Inc. Compound, resist composition, and method for forming resist pattern using it
US11480877B2 (en) 2015-03-31 2022-10-25 Mitsubishi Gas Chemical Company, Inc. Resist composition, method for forming resist pattern, and polyphenol compound used therein
US11137686B2 (en) 2015-08-31 2021-10-05 Mitsubishi Gas Chemical Company, Inc. Material for forming underlayer film for lithography, composition for forming underlayer film for lithography, underlayer film for lithography and production method thereof, and resist pattern forming method
US11143962B2 (en) 2015-08-31 2021-10-12 Mitsubishi Gas Chemical Company, Inc. Material for forming underlayer film for lithography, composition for forming underlayer film for lithography, underlayer film for lithography and production method thereof, pattern forming method, resin, and purification method
US11243467B2 (en) 2015-09-10 2022-02-08 Mitsubishi Gas Chemical Company, Inc. Compound, resin, resist composition or radiation-sensitive composition, resist pattern formation method, method for producing amorphous film, underlayer film forming material for lithography, composition for underlayer film formation for lithography, method for forming circuit pattern, and purification method
US11572430B2 (en) 2015-09-10 2023-02-07 Mitsubishi Gas Chemical Company, Inc. Compound, resin, resist composition or radiation-sensitive composition, resist pattern formation method, method for producing amorphous film, underlayer film forming material for lithography, composition for underlayer film formation for lithography, method for forming circuit pattern, and purification method
JP2018154600A (en) * 2017-03-21 2018-10-04 三菱瓦斯化学株式会社 Compound, resin, composition, patterning method, and purifying method

Also Published As

Publication number Publication date
JP3498857B2 (en) 2004-02-23

Similar Documents

Publication Publication Date Title
JP4039870B2 (en) Cosmetics with triple stabilization of retinol
JP3405740B2 (en) Cosmetic and pharmaceutical compositions
JP3498857B2 (en) External preparation for skin
AU606200B2 (en) Compositions for topical use having melanin synthesis- inhibiting activity
JPH09510723A (en) Compositions for treatment of skin
KR102301123B1 (en) Cosmetic composition comprising retiniol steblized by mixed antioxidant
JPH05320036A (en) Composition for eliminating singlet oxygen
CN113101236A (en) Instant mixed and used whitening essence with multiple antioxidation effects and preparation method thereof
JPS6323737A (en) Method for promoting formation of niosome dispersed in aqueous phase and improving stability and encapsulation property thereof
CA2244535A1 (en) Novel uses for ascorbyl-phosphoryl-cholesterol in topical compositions
EP3562465B1 (en) Novel antioxidants for cosmetics and pharmaceutical compositions containing glycerol alkyl ethers
EP1370241B1 (en) Multi-lamellar emulsion(mle) for stabilizing dermatologically useful ingredients and external base preparations for general skin diseases utilizing the same
JP2903240B2 (en) External preparation for skin
JPH0867621A (en) Skin activator having glycosaminoglycan production-accelerating action
JP2665976B2 (en) Cosmetics
JP2799568B2 (en) Antioxidant composition
JP2799569B2 (en) Antioxidant composition
JPH08151575A (en) Antioxidant and skin preparation for external use containing the same blended therein
JP2023507769A (en) Combination of vitamin A and vitamin C with improved stability
JP4537545B2 (en) Cosmetics
JPH01283208A (en) Beautifying cosmetic
EP0445735A1 (en) Melanogenesis-inhibiting endermic preparation
JPS63254181A (en) Antioxidant composition
JPH05213735A (en) Beautifully whitening cosmetic
JPH0733639A (en) Beautifying and whitening cosmetic

Legal Events

Date Code Title Description
LAPS Cancellation because of no payment of annual fees